Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection

Our data suggest that trimethobenzamide helps reduce nausea/vomiting during the first 8 weeks of apomorphine therapy, but is generally not needed thereafter. Trimethobenzamide did not worsen parkinsonism nor affect “on” response after apomorphine injection.